Literature DB >> 22563781

Allergen-specific responses of CD19(high) and CD19(low) B Cells in Non-IgE-mediated food allergy of late eczematous reactions in atopic dermatitis: presence of IL-17- and IL-32-producing regulatory B cells (Br17 & Br32).

Joonyong Noh1, Geunwoong Noh.   

Abstract

BACKGROUND: Food allergies are important etiologic factors in atopic dermatitis. CD19 is a B-cell-specific cell-surface molecule, with a critical role in B-cell activation. Recently, B cells showed independent two subpopulations as CD19(high) and CD19(low). The allergen-specific responses of the CD19(high) and CD19(low) B-cell subpopulations were investigated in patients with non-IgE-mediated food allergy.
METHODS: Five milk-allergic subjects and eight milk-tolerant subjects were selected by a double-blind placebo-controlled food challenge. Peripheral blood mononuclear cells (PBMCs) were stimulated in vitro with casein or ovalbumin and stained with monoclonal antibodies to distinguish the B-cell subsets.
RESULTS: After allergen stimulation, CD19(high) B cells increased in the number and the fraction in PBMCs in the milk-tolerant group, whereas those remained unchanged in the milk-allergic group. These responses were constant, regardless of the kind of food allergen (milk or egg). The resulting CD19(high)/CD19(low) B-cell ratio increased markedly in the milk-tolerant group after allergen stimulation, but was unchanged in the milk-allergic group. IL-10, IL-17, IL-32 and TGF-β- producing regulatory B cells and Foxp3-expressing regulatory B cells were identified predominantly on CD19 low and CD5(+) B cells.
CONCLUSIONS: The response of the CD19(high) B-cell subpopulation to allergen stimulation is decisive for immune tolerance of non-IgE-mediated food allergy in atopic dermatitis. CD19 high and CD5(+) B cells dominantly produce cytokines and express Foxp3. Especially, IL-17 and IL-32 expressing B cells (Br17 & Br32) are present. The exact immunological role of CD19 and cytokines including IL-17 and IL-32 around B cells in immune tolerance requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22563781     DOI: 10.2174/187152812800959022

Source DB:  PubMed          Journal:  Inflamm Allergy Drug Targets        ISSN: 1871-5281


  7 in total

1.  Potential Role for Regulatory B Cells as a Major Source of Interleukin-10 in Spleen from Plasmodium chabaudi-Infected Mice.

Authors:  Xue Han; Ji Yang; Yitong Zhang; Yalin Zhang; Hongtao Cao; Yaming Cao; Zanmei Qi
Journal:  Infect Immun       Date:  2018-04-23       Impact factor: 3.441

Review 2.  Clinical spectrum of food allergies: a comprehensive review.

Authors:  Marco H-K Ho; Wilfred H-S Wong; Christopher Chang
Journal:  Clin Rev Allergy Immunol       Date:  2014-06       Impact factor: 8.667

Review 3.  FoxP3 Expression in Macrophages, Cancer, and B Cells-Is It Real?

Authors:  Zahava Vadasz; Elias Toubi
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667

4.  Increased plasma interleukin-32 expression in patients with neuromyelitis optica.

Authors:  Honghao Wang; Kai Wang; Conghui Wang; Fangcheng Xu; Wei Qiu; Xueqiang Hu
Journal:  J Clin Immunol       Date:  2012-11-21       Impact factor: 8.317

5.  Analysis of Peripheral B Cell Subsets in Patients With Allergic Rhinitis.

Authors:  Jing Luo; Huanhuan Guo; Zhuofu Liu; Tao Peng; Xianting Hu; Miaomiao Han; Xiangping Yang; Xuhong Zhou; Huabin Li
Journal:  Allergy Asthma Immunol Res       Date:  2018-05       Impact factor: 5.764

6.  Effect of type of TAG fatty acids on lutein and zeaxanthin bioavailability.

Authors:  Béatrice Gleize; Franck Tourniaire; Laurence Depezay; Romain Bott; Marion Nowicki; Lionel Albino; Denis Lairon; Emmanuelle Kesse-Guyot; Pilar Galan; Serge Hercberg; Patrick Borel
Journal:  Br J Nutr       Date:  2012-12-11       Impact factor: 3.718

7.  The Expansion of CD25 high IL-10 high FoxP3 high B Regulatory Cells Is in Association with SLE Disease Activity.

Authors:  Zahava Vadasz; Regina Peri; Nasren Eiza; Gleb Slobodin; Alexandra Balbir-Gurman; Elias Toubi
Journal:  J Immunol Res       Date:  2015-10-04       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.